Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Abbott and Medtronic DES double hit likely to increase impact on competitors

This article was originally published in Clinica

Executive Summary

Abbott's Xience and Medtronic's Endeavor are highly likely to reach the US market at the same time - during the first quarter of 2008 - causing a bigger than expected impact on competing firms, say analysts. The double approval will mean that rivals Boston Scientific and J&J will not have time "to establish a foothold against newer entrants", said Morgan Stanley analyst Glenn Reicin. The prediction comes after Mr Reicin reported that the FDA has approved the manufacturing facility where Xience is to be produced. If the Xience DES is approved by the end of the first quarter, it could add $150m to Abbott's 2008 sales, said the analyst.

You may also be interested in...

Pipeline Acquisitions, Co-Promotion Deals, To Drive Ipsen

Ipsen’s business strategy calls for accessing external innovation across its pipeline, combined with geographic expansion, realizing the unmet potential of its marketed products and business efficiencies in manufacturing and operations.

Biden COVID-19 Plan Would Grow Domestic Manufacturing Base

The proposal, which would increase capacity for pandemic supplies, is similar to ideas President Trump embraced pre-pandemic.

People On The Move: Appointments At Sanofi, Enzymatica And Bayer

Sanofi has named the head of its new API business; Sweden's Enzymatica has hired talent from J&J and L'Oreal; and Bayer has a new transformation officer.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts